Jump to content

British HIV Association

From Wikipedia, the free encyclopedia
(Redirected from BHIVA)
British HIV Association
AbbreviationBHIVA
Established1995
Location
Chair
Yvonne Gilleece
Websitewww.bhiva.org

The British HIV Association (BHIVA) is an organisation of healthcare professionals interested in the treatment and care of people with HIV.

The current BHIVA Chair is Prof. Yvonne Gilleece.[1]

The aims of BHIVA are, to advance:

  • Promotion of good practice in the treatment of HIV
  • Public education through the promotion and dissemination of research[2]

Conferences

[edit]

BHIVA holds two national conferences per year, the BHIVA National Conference in April and the BHIVA Autumn Conference.[3]

Guidelines

[edit]

BHIVA produce guidelines which are accredited by the UK National Institute for Health and Care Excellence (NICE).[4]

Guidelines produced by BHIVA include:

  • Pre-exposure prophylaxis (PrEP) guidelines[5]
  • Treatment of HIV-1 positive adults[6]
  • Use of Vaccines in HIV-positive adults[7]
  • Post-exposure prophylaxis (PEP) guidelines[8]
  • Opportunistic infection in HIV-positive individuals[9]

See also

[edit]

References

[edit]
  1. ^ "Executive Committee". www.bhiva.org. Retrieved 2020-04-19.
  2. ^ Orkin, Chloe. "Kings Fund Concluding Remarks" (PDF). www.kingsfund.org.uk. Retrieved 12 September 2017.
  3. ^ i-base (12 September 2017). "i-base Future Meetings". i-base.
  4. ^ NICE (12 September 2017). "NICE Accreditation Decisions".
  5. ^ Brady, Michael; et al. (14 March 2019). "BHIVA/BASHH guidelines on the use of HIV pre–exposure prophylaxis (PrEP) 2018". HIV Medicine. 20 (S2): s2–s80. doi:10.1111/hiv.12718. PMID 30869189.
  6. ^ Churchill, Duncan; et al. (17 Aug 2016). "British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015" (PDF). HIV Medicine. 17 (s4): s2–s104. doi:10.1111/hiv.12426. PMID 27568911. S2CID 32394203.
  7. ^ Geretti, AM; et al. (17 Aug 2016). "British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015" (PDF). HIV Medicine. 17 (s3): s2–s81. doi:10.1111/hiv.12424. PMID 27568789. S2CID 142893.
  8. ^ Cresswell, Fiona; et al. (27 Aug 2016). "UK guideline for the use of HIV Post-Exposure Prophylaxis Following Sexual Exposure, 2015" (PDF). Int J STD AIDS. 27 (9): 713–38. doi:10.1177/0956462416641813. PMID 27095790. S2CID 33255206.
  9. ^ Nelson, M; et al. (Sep 2011). "British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011". HIV Medicine. 12 (S2): 1–140. doi:10.1111/j.1468-1293.2011.00944_1.x. PMID 21851517. S2CID 22513510.